The BioMarin Pharmaceutical Inc (BMRN) share price is expected to increase by 24.99% over the next year. This is based on calculating the average 12-month share price estimate provided by 11 stock analysts who have covered BMRN. Price targets range from $85.00 at the low end to $170.00 at the high end. The current analyst consensus for BMRN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 11 Wall Street analysts have assigned BMRN 8 buy ratings, 3 hold ratings, and 0 sell ratings. This means that analysts expect BioMarin Pharmaceutical Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on BMRN. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
olivia brayer Cantor Fitzgerald | Buy | $100.0 | maintained | Feb 22, 2024 |
jessica fye J.P. Morgan | Buy | $111.0 | maintained | Feb 20, 2024 |
akash tewari Jefferies | Buy | $133.0 | maintained | Feb 20, 2024 |
jack allen Robert W. Baird | Buy | $104.0 | maintained | Jan 30, 2024 |
paul matteis Stifel Nicolaus | Buy | $101.0 | maintained | Jan 26, 2024 |
mohit bansal Wells Fargo | Buy | $100.0 | maintained | Jan 25, 2024 |
kostas biliouris BMO Capital | Buy | $115.0 | maintained | Jan 9, 2024 |
joseph schwartz Leerink Partners | Buy | None | reiterated | Jan 8, 2024 |
geoff meacham Bank of America Securities | Buy | $170.0 | maintained | Jan 8, 2024 |
david lebovitz Citi | Hold | $85.0 | maintained | Jan 8, 2024 |
luca issi RBC Capital | Hold | $100.0 | maintained | Jan 3, 2024 |
william pickering Bernstein | Hold | $93.0 | maintained | Jan 2, 2024 |
phil nadeau TD Cowen | Buy | $125.0 | maintained | Nov 30, 2023 |
leland gershell Oppenheimer | Hold | None | maintained | Nov 7, 2023 |
salveen richter Goldman Sachs | Buy | $138.0 | reiterated | Nov 7, 2023 |
whitney ijem Canaccord Genuity | Hold | $91.0 | maintained | Nov 6, 2023 |
robyn karnauskas Truist Financial | Buy | $140.0 | maintained | Nov 2, 2023 |
gena wang Barclays | Buy | $111.0 | maintained | Nov 2, 2023 |
christopher raymond Piper Sandler | Buy | $115.0 | maintained | Nov 2, 2023 |
andreas argyrides Wedbush | Hold | $78.0 | reiterated | Nov 2, 2023 |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
When did it IPO
1999
Staff Count
3,082
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Alexander Hardy
Market Cap
$16.68B
In 2023, BMRN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that BMRN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
FSLR-USD
$150.03
$117.9
NTRS-USD
$79.95
AKAM-USD
$106.95
$44.99
ENPH-USD
$126.24